The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.


Updates from The Motley Fool

Latest updates on Biogen from Fool.com.


Stock Performance

BIIB vs. S&P 500 | 2 Year Performance
View Interactive BIIB Charts
Sponsored by

Key Data Points

Primary metrics and data points about Biogen.
Current Price: $308.17
Prev Close: $308.17
Open: $307.21
Bid: $301.19
Ask: $308.55
Day's Range: $304.56 - $310.74
52wk Range: $223.02 - $333.65
Volume: 1,122,094
Avg Vol 2,124,099
Market Cap: $68.69B
P/E (ttm): 21.67
EPS (ttm): $14.16
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Biogen.
CAPS Rating 5 out of 5
 
1002 Outperform
71 Underperform
CAPS All Stars
 
257 Outperform
12 Underperform

How do you think Biogen will perform against the market?



You pick for Biogen is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

George A. Scangos, CEO

82% Approve

Based on 248 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Biogen.

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers